Aethlon Medical Inc
$ 1.90
-5.94%
11 Jun - close price
- Market Cap 4,504,100 USD
- Current Price $ 1.90
- High / Low $ 2.01 / 1.81
- Stock P/E N/A
- Book Value 6.90
- EPS -10.61
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.67 %
- ROE -1.43 %
- 52 Week High 27.40
- 52 Week Low 1.36
About
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life- and organ-threatening diseases in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$4.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-12 | 2025-08-13 | 2025-06-26 | 2025-02-12 | 2024-11-13 | 2024-08-14 | 2024-06-27 | 2024-02-14 | 2023-11-14 | 2023-08-10 | 2023-06-28 |
| Reported EPS | -2.45 | -3.74 | -8.5 | -3.44 | -10.4 | -16 | -27.2 | -0.91 | -109.6 | -97.6 | -112 | -0.1 |
| Estimated EPS | -2.01 | -3.66 | -7.3 | -1.11 | -16.27 | -15.6 | -25.2 | -1.25 | -109.33 | -112 | -104 | -0.13 |
| Surprise | -0.44 | -0.08 | -1.2 | -2.33 | 5.87 | -0.4 | -2 | 0.34 | -0.27 | 14.4 | -8 | 0.03 |
| Surprise Percentage | -21.8905% | -2.1858% | -16.4384% | -209.9099% | 36.0787% | -2.5641% | -7.9365% | 27.2% | -0.247% | 12.8571% | -7.6923% | 23.0769% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AEMD
2026-06-11 21:09:16
Aethlon Medical, Inc. (AEMD) has reported no revenue for fiscal years 2025 and 2026 and continues to incur significant losses, leading auditors to raise substantial doubt about its ability to continue as a going concern for the next 12 months. Despite these financial challenges, the company is advancing its Hemopurifier device through clinical trials, particularly an oncology study in Australia, and is actively seeking additional capital through equity financings. The Hemopurifier remains a clinical-stage investigational device focused on oncology and life-threatening viral infections, with positive safety data reported from initial cohorts of its Australian oncology trial.
2026-06-11 02:09:16
Aethlon Medical (AEMD) is progressing with its Hemopurifier oncology trial, announcing plans to expand cohort 3 to include 3 to 6 patients, up from the original 3. This expansion follows positive safety and feasibility data from the initial 3-patient cohort, allowing more patients to receive treatment with the Hemopurifier. The trial aims to evaluate the device's ability to remove tumor-derived exosomes in metastatic cancer patients undergoing immunotherapy.
2026-06-11 00:09:16
Aethlon Medical reported its financial results for the fiscal year ended March 31, 2026, highlighting progress on its Hemopurifier platform, including clinical research, intellectual property milestones, and expansion into oncology and other disease areas. The company emphasized disciplined cost control throughout the fiscal year. The earnings release also included forward-looking statements subject to risks detailed in SEC filings.
2026-06-10 22:09:16
Aethlon Medical (AEMD) reported Q4 2026 earnings, highlighting a significant reduction in net loss and operating expenses due to disciplined cost control. The company is advancing its Australian oncology trial to cohort 3 after favorable safety reviews and is expanding preclinical research into rheumatoid arthritis and chronic kidney disease. Aethlon also confirmed that its FDA-approved compassionate use protocol for Ebola remains active, and initial compatibility tests with a simplified blood pump system were successful.
2026-06-10 21:09:16
Aethlon Medical Inc. reported its fiscal year 2026 financial results, including a comprehensive loss of $7.17 million and a net loss attributable to common stockholders of $7.15 million, with a diluted loss per share of $10.61. These figures represent an improvement compared to fiscal 2025. The company also highlighted progress in its clinical trials, regulatory momentum with FDA Breakthrough Device designation, and advancements in manufacturing and capital operations.
2026-06-10 20:09:16
Aethlon Medical Inc. (AEMD) reported a significant narrowing of its net loss for FY 2026, down to $7.2 million from $13.4 million in the prior year, driven by a 21.9% reduction in operating expenses. The company also advanced its Hemopurifier Australian oncology trial into the third and final dosing cohort and secured new patents for COVID-19 and Long COVID applications. These developments highlight progress in both financial management and clinical pipeline, positioning Aethlon Medical for future growth.
